Guardant Health (GH) traded lower Monday, April 6, 2026, down 3.08% to $90.59. A scan of the latest publicly available items did not surface a new Guardant press release or clearly identifiable, same-day fundamental catalyst that would typically explain a discrete move of this size.

In the absence of a company-specific headline, today’s drop looks consistent with routine liquidity-driven selling—investors trimming risk, rotating out of recent winners, or responding to broader weakness in high-multiple healthcare/diagnostics names. Guardant also has had recent capital-structure headlines in the past several months, including a convertible-notes financing alongside a common stock offering, which can create intermittent “financing overhang” narratives even after deals are completed as investors reassess dilution and hedging dynamics.

Guardant last provided a formal 2026 outlook with its Q4 and full-year 2025 results (released February 19, 2026), which set investor expectations for growth and spending this year. Separately, the company’s late-2025 financing activity remains part of the stock’s backdrop and can influence trading behavior—particularly for a name with a large retail and momentum following and an active options market.